A Study of the Curative Effect of Entecavir and Tongluo Ruanjian Capsule for Patients with Posthepatitic Cirrhosis and Their Effect on Liver Function and Liver Fibrosis
SHEN Lixian, WANG Xiaoling, LI Huiwen
Hebei Hepatopathy Hospital of Traditional Chinese Medicine, Hebei Shijiazhuang 050800, China
Abstract：Objective: To explore the clinical effect of entecavir and Tongluo Ruanjian capsule in the treatment of liver fibrosis after hepatitis B, and to observe the influence of entecavir and Tongluo Ruanjian Capsule on serum indexes, liver function and liver fibrosis. Methods: From January 2015 to January 2017, 120 patients with liver fibrosis after hepatitis B were collected as the study object, and divided into control group and observation group with simple random number table method, 60 cases in each group. Both groups were given basic treatment, including vitamin, diammonium glycyrrhizinate enteric coated capsules, etc. On this basis, the patients in the control group were additionally administered with entecavir tablets; the patients in the observation group were additionally administered with Tongluo Ruanjian capsule. Both groups were treated for 6 months and 2 courses. The changes of serum matrix metalloproteinase-13 (MMP-13), tumor necrosis factor α (TNF - α), transforming growth factor β 1 (TGF - β 1), international standard ratio (INR) and end-stage liver disease model score (MELD) were observed and evaluated before and after treatment. The changes of liver function indexes and liver fibrosis indexes were compared before and after treatment. The clinical efficacy and adverse reactions of the two groups were observed and recorded, and the safety of the two groups was evaluated. Results: After two courses of treatment, the total effective rate of clinical treatment in the observation group was 95.00% (57 / 60), significantly higher than 81.67% (49 / 60) in the control group, and the difference was statistically significant (P < 0.01). The serum inflammatory indexes (MMP-13, TNF - α, TGF - β 1), liver function indexes (ALT, GGT, TB), INR and MELD scores in the two groups were significantly lower than those before treatment, and the improvement degree of each index in the observation group was more significant than that in the control group, with statistical significance (P < 0.01). The index of liver fibrosis in the observation group was significantly lower than that in the control group (P < 0.01). During the treatment, no serious adverse reactions were found in the two groups. Conclusion: Entecavir tablet combined with Tongluo Ruanjian capsule has obvious curative effect for patients with liver fibrosis after hepatitis B, which can significantly improve the liver function and liver fibrosis index, and it is safe.
沈丽贤, 王晓玲, 李惠文. 通络软坚胶囊联合恩替卡韦分散片治疗乙肝后肝纤维化的临床疗效及对相关指标的影响[J]. 河北医学, 2020, 26(7): 1220-1224.
SHEN Lixian, WANG Xiaoling, LI Huiwen. A Study of the Curative Effect of Entecavir and Tongluo Ruanjian Capsule for Patients with Posthepatitic Cirrhosis and Their Effect on Liver Function and Liver Fibrosis. HeBei Med, 2020, 26(7): 1220-1224.
2020, Vol. 26 
冀公网安备13080202000677号